Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 3Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine 6Cyclophosphamide 5fludarabine phosphate 4Whole-Body Irradiation 4itacitinib 3angiotensin I (1-7) 3pembrolizumab 2Tacrolimus 2Olanzapine 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2INCB039110 2CTLA-4 Antigen 2Busulfan 2Brentuximab Vedotin 2Bendamustine Hydrochloride 2AP 1903 reagent 2tazemetostat 1tafasitamab 1ruxolitinib 1pomalidomide 1ofatumumab 1merphos 1lopinavir-ritonavir drug combination 1ivosidenib 1ibrutinib 1fedratinib 1enasidenib 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hematologic Neoplasms × Leukapheresis × Clear all
NCT01326273 2015-06-08

Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation

Imperial College London

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡